Want to see EMMA full AI Analyst Report?
Emmaus Life Sciences (EMMA) Stock Statistics & Valuation Metrics
Total Valuation
Emmaus Life Sciences has a market cap or net worth of $2.47M. The enterprise value is $28.94M.
- Market Cap
- $2.47M
- Enterprise Value
- $28.94M
Share Statistics
Emmaus Life Sciences has 70,188,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 70,188,260
- Owned by Insiders
- 1.89%
- Owned by Institutions
- 0.08%
Financial Efficiency
Emmaus Life Sciences’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is -1.23%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- -0.35
- Return on Invested Capital (ROIC)
- -1.23%
- Return on Capital Employed (ROCE)
- -0.00
- Revenue Per Employee
- 377.36K
- Profits Per Employee
- -227.03K
- Employee Count
- 33
- Asset Turnover
- 0.58
- Inventory Turnover
- 0.55
Valuation Ratios
The current PE Ratio of Emmaus Life Sciences is -0.37. Emmaus Life Sciences’s PEG ratio is 0.00.
- PE Ratio
- -0.37
- PS Ratio
- 0.16
- PB Ratio
- -0.04
- Price to FCF
- 0.62
- Price to Operating Cash Flow
- 0.62
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Emmaus Life Sciences had revenue of 12.45M and earned -7.49M in profits. Earnings per share was -0.12.
- Revenue
- 12.45M
- Gross Profit
- 11.60M
- Operating Income
- 231.00K
- Pretax Income
- -7.48M
- Net Income
- -7.49M
- EBITDA
- -310.00K
- Earnings Per Share (EPS)
- -0.12
Cash Flow
In the last 12 months, operating cash flow was 3.97M and capital expenditures -2,000, giving a free cash flow of 3.96M billion.
- Operating Cash Flow
- 3.97M
- Free Cash Flow
- 3.96M
- Free Cash Flow per Share
- 0.06
Dividends & Yields
Emmaus Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 160.49%
- Earnings Yield
- -243.82%
Stock Price Statistics
- Beta
- -1.44
- 52-Week Price Change
- 250.00%
- 50-Day Moving Average
- 0.06
- 200-Day Moving Average
- 0.02
- Relative Strength Index (RSI)
- 40.13
- Average Volume (3m)
- 156.81K
Important Dates
Emmaus Life Sciences upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Emmaus Life Sciences as a current ratio of 0.11, with Debt / Equity ratio of -51.19%
- Current Ratio
- 0.11
- Quick Ratio
- 0.09
- Debt to Market Cap
- 37.00
- Net Debt to EBITDA
- -98.17
- Interest Coverage Ratio
- 0.03
Taxes
In the past 12 months, Emmaus Life Sciences has paid 9,000 in taxes.
- Income Tax
- 9,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Emmaus Life Sciences EV to EBITDA ratio is 8.88, with an EV/FCF ratio of 7.61.
- EV to Sales
- 1.94
- EV to EBITDA
- 8.88
- EV to Free Cash Flow
- 7.61
- EV to Operating Cash Flow
- 7.61
Balance Sheet
Emmaus Life Sciences has $2.81M in cash and marketable securities with $30.52M in debt, giving a net cash position of -$27.72M billion.
- Cash & Marketable Securities
- $2.81M
- Total Debt
- $30.52M
- Net Cash
- -$27.72M
- Net Cash Per Share
- -$0.39
- Tangible Book Value Per Share
- -$0.94
Margins
Gross margin is 93.60%, with operating margin of 29.29%, and net profit margin of -38.79%.
- Gross Margin
- 93.60%
- Operating Margin
- 29.29%
- Pretax Margin
- -34.93%
- Net Profit Margin
- -38.79%
- EBITDA Margin
- 21.89%
- EBIT Margin
- 21.60%
Analyst Forecast
The average price target for Emmaus Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 10.98%
- EPS Growth Forecast
- -72.08%
Scores
- Smart Score
- ―
- AI Score
- 42
